Corline Biomedical AB

Corline Biomedical AB is a Swedish life sciences company specializing in the development and commercialization of heparin-based solutions for medical devices and regenerative medicine. The company's core technology platforms, Corline Heparin Surface (CHS™) and Corline Heparin Conjugate (CHC™), utilize a proprietary macromolecular heparin conjugate to improve the biocompatibility of implants and protect transplanted organs and cells from immune-mediated thrombosis and inflammation. The company operates with a dual-track business model. In the medical technology sector, it out-licenses its CHS™ coating technology to partners for use in cardiac, neurovascular, and other high-performance medical devices. In the regenerative medicine sector, Corline is developing its own drug candidates, most notably Renaparin®, which is designed to prevent ischemia-reperfusion injury in kidney transplantation, and Cytoparin™, focused on improving outcomes in cell therapies such as islet cell transplantation for Type 1 diabetes.